Wednesday, July 28, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

What General Medical Oncologists Want to Know About Immunotherapy and Other Nontargeted Approaches for Lung Cancer

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Wednesday, July 28th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Mark Awad, MD, PhD
Clinical Director
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David R Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Heather Wakelee, MD
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
Deputy Director, Stanford Cancer Institute
Stanford, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc and Turning Point Therapeutics Inc.

Current Treatment Paradigm for Small Cell Lung Cancer (SCLC)

  • Key efficacy and safety findings from the pivotal Phase III IMpower133 and CASPIAN trials evaluating atezolizumab and durvalumab, respectively, in combination with chemotherapy for patients with previously untreated extensive-stage SCLC (ES-SCLC)
  • Entry criteria and key primary and secondary endpoints of the Phase III LUMINANCE trial of durvalumab in combination with platinum/etoposide and the Phase III SKYSCRAPER-02 trial of atezolizumab in combination with carboplatin/etoposide with or without tiragolumab for patients with previously untreated ES-SCLC
  • Appropriate integration of first-line carboplatin/etoposide/atezolizumab and platinum/etoposide/ durvalumab into SCLC management
  • Available clinical trial data with and current role of immune checkpoint inhibitors for progressive ES-SCLC
  • Design, eligibility criteria and key endpoints of the Phase III ADRIATIC study assessing durvalumab alone or in combination with tremelimumab as consolidation therapy for patients with limited-stage SCLC (LS-SCLC) who have not experienced disease progression after concurrent chemoradiation therapy
  • Ongoing Phase III KEYLYNK-013 trial evaluating concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab and olaparib in patients with newly diagnosed LS-SCLC
  • Major efficacy and safety findings of the Phase II basket trial assessing lurbinectedin for patients with SCLC who have experienced disease progression after platinum-based therapy; recent FDA approval and current clinical role
  • Design, entry criteria and emerging negative results from the Phase III ATLANTIS trial of lurbinectedin/doxorubicin as second-line therapy for patients with SCLC; implications for clinical practice

Current and Potential Role of Immune Checkpoint Inhibition in the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC)

  • Available efficacy outcomes from early-phase trials of immune checkpoint inhibitors alone and in combination with chemotherapy for early-stage NSCLC in the neoadjuvant setting
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for patients with resectable NSCLC
  • Emerging indications of improved rates of pathologic complete response with the addition of nivolumab to neoadjuvant chemotherapy in CheckMate 816; clinical implications
  • Long-term efficacy and safety findings from the Phase III PACIFIC trial evaluating durvalumab as consolidation after chemoradiation therapy for patients with unresectable Stage III NSCLC; patient selection for and practical implementation of consolidation durvalumab
  • Primary efficacy and safety results from the Phase III IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy for resected Stage IB to IIIA NSCLC
  • Recognition and management of immune-related adverse events associated with immune checkpoint inhibitor-based therapies
  • Other ongoing and planned clinical trials of immune checkpoint inhibitors for patients with nonmetastatic NSCLC (eg, PACIFIC-2, PACIFIC-4, IMpower030, AEGEAN, KEYNOTE-671)

Long-Term Management of Metastatic NSCLC without a Targetable Tumor Mutation

  • Published efficacy and safety outcomes from the Phase III trial of cemiplimab monotherapy versus chemotherapy as first-line treatment for patients with PD-L1-positive locally advanced or metastatic NSCLC; recent FDA approval of cemiplimab and optimal integration into clinical management
  • Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab administered as monotherapy and combined with chemotherapy as first-line treatment for metastatic NSCLC
  • Updated results from the Phase III CheckMate 9LA and CheckMate 227 trials leading to the FDA approvals of first-line nivolumab/ipilimumab with and without chemotherapy for patients with metastatic NSCLC
  • Recently presented findings from the Phase III KEYNOTE-598 trial revealing a lack of benefit with ipilimumab in combination with pembrolizumab compared to pembrolizumab alone as first-line therapy for patients with PD-L1-positive (tumor proportion score ≥50%) metastatic NSCLC
  • Clinical and biologic factors in the choice of anti-PD-1/PD-L1 monotherapy, combined chemoimmunotherapy or dual immune checkpoint inhibition for patients with nonsquamous or squamous metastatic NSCLC
  • Rationale for the design of the ongoing Phase III KEYLYNK-008 trial of pembrolizumab in combination with chemotherapy followed by pembrolizumab with or without maintenance olaparib in the first-line treatment of squamous metastatic NSCLC
  • Management of disease that has progressed on anti-PD-1/PD-L1-based therapy in the first-line setting; current role of approved agents and regimens (eg, ramucirumab, afatinib, bevacizumab)
  • Mechanisms of action of tislelizumab and ociperlimab; ongoing Phase III trial comparing tislelizumab/ociperlimab to single-agent pembrolizumab or ociperlimab as first-line therapy for patients with PD-L1-selected unresectable locally advanced or metastatic NSCLC
  • Other novel immune checkpoint inhibitor-based combination strategies (eg, coformulated vibostolimab with pembrolizumab) under investigation for patients with metastatic NSCLC
  • Mechanism of action of sintilimab; ongoing Phase II trial of sintilimab in combination with docetaxel for previously treated locally advanced or metastatic NSCLC
  • Ongoing Phase III trials evaluating immunotherapy-based combinations for previously untreated or treated metastatic NSCLC (eg, ZEAL-1L, LEAP-008)

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

Learning Objectives

  • Analyze the biologic basis for the investigation of immune checkpoint inhibitors for patients with nonmetastatic non-small cell lung cancer (NSCLC), and evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches to neoadjuvant and adjuvant therapy.
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately integrate this strategy into routine clinical practice.
  • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for patients with previously untreated extensive-stage small cell lung cancer (SCLC).
  • Consider the FDA approval of lurbinectedin for patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy, and discern how this agent can be optimally employed in nonresearch therapy.
  • Design an optimal approach to the clinical care of patients with progressive SCLC, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Acknowledge available Phase III findings supporting the recent FDA approval of cemiplimab as first-line therapy for PD-L1-positive NSCLC without EGFR, ALK or ROS1 aberrations, either locally advanced in patients not eligible for surgical resection or definitive chemoradiation or in those with metastatic disease.
  • Recognize the recent FDA approvals of nivolumab in combination with ipilimumab with and without chemotherapy as first-line therapy for metastatic NSCLC, and appropriately incorporate these novel regimens into treatment algorithms.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic NSCLC, and discern how these approaches can be optimally employed in disease management.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc and Turning Point Therapeutics Inc.